First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy

This is the fi rst study of a STAT3-selective inhibitor in humans and the fi rst evidence that a transcription factor decoy can be modifi ed to enable systemic delivery. These findings have therapeutic implications beyond STAT3 to other “undruggable” targets in human cancers.

ClinicalTrials.gov NCT00696176.